SNPHY News and Press, Santen Pharmaceutical Co. Ltd. ADR From 12/07/21

Aerie Pharmaceuticals (NASDAQ:AERI) and Santen (OTC:SNPHF) have entered into an exclusive development and commercialization agreement for Rhopressa/Rhokiinsa (netarsudil ophthalmic solution) 0.02% and Rocklatan/Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expand...

The following slide deck was published by Santen Pharmaceutical Co., Ltd. in conjunction with their 2021 Q2 earnings call. For further details see: Santen Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation

Santen Pharmaceutical (OTCPK:SNPHY): 1H Non-GAAP EPS of ¥46.41; GAAP EPS of ¥35.73. Revenue of $¥128.76B (+8.3% Y/Y) Press Release For further details see: Santen Pharmaceutical reports 1H results

The following slide deck was published by Santen Pharmaceutical Co., Ltd. in conjunction with their 2021 Q1 earnings call. For further details see: Santen Pharmaceutical Co., Ltd. 2021 Q1 - Results - Earnings Call Presentation

Santen Pharmaceutical Co., Ltd. (OTCPK:SNPHY): FQ1 Non-GAAP EPS of ¥22.56; GAAP EPS of ¥18.44. Revenue of ¥64.98B (+12.9% Y/Y). Press Release For further details see: Santen Pharmaceutical Co. reports FQ1 results

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affiliated Managers Group. The Glob...

The following slide deck was published by Santen Pharmaceutical Co., Ltd. in conjunction with their 2021 Q4 earnings call. For further details see: Santen Pharmaceutical Co., Ltd. 2021 Q4 - Results - Earnings Call Presentation

Santen Pharmaceutical Co., Ltd. (SNPHY): FY Non-GAAP EPS of ¥93.87; GAAP EPS of ¥17.06.Revenue of ¥249.6B (+3.3% Y/Y)Press Release For further details see: Santen Pharmaceutical Co., Ltd. reports FY results

Opthea has filed proposed terms to raise capital from a U.S. IPO. The firm is developing a treatment for Wet AMD and other eye conditions. OPT has produced impressive Phase 2b efficacy trial results for its lead candidate, so the IPO is worth considering for long-term hold life sc...

OSAKA, Japan and SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San Diego, CA; hereinafter, “TRACON”) today announced the discontinuation of ...